OTCPK:CTTC

Stock Analysis Report

Executive Summary

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Calmare Therapeutics has significant price volatility in the past 3 months.
  • Calmare Therapeutics's last earnings update was 726 days ago.
  • Calmare Therapeutics is not covered by any analysts.

Share Price & News

How has Calmare Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

44.4%

OTCPK:CTTC

-0.4%

US Medical Equipment

-0.3%

US Market


1 Year Return

63.6%

OTCPK:CTTC

14.3%

US Medical Equipment

3.4%

US Market

CTTC outperformed the Medical Equipment industry which returned 13.5% over the past year.

CTTC outperformed the Market in United States of America which returned 4.1% over the past year.


Share holder returns

CTTCIndustryMarket
7 Day44.4%-0.4%-0.3%
30 Day34.2%3.1%2.9%
90 Day184.1%12.8%2.1%
1 Year63.6%63.6%15.3%14.3%5.7%3.4%
3 Year-10.5%-10.5%66.7%61.4%45.8%36.2%
5 Year-27.4%-27.4%128.7%101.8%58.9%41.3%

Price Volatility Vs. Market

How volatile is Calmare Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Calmare Therapeutics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Calmare Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Calmare Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Calmare Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Calmare Therapeutics regulatory filings here.
  • Explore potentially undervalued companies in the healthcare industry.

Future Growth

How is Calmare Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.9%

Forecasted Medical Equipment industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Calmare Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Calmare Therapeutics performed over the past 5 years?

15.0%

Historical Medical Equipment annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Calmare Therapeutics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Calmare Therapeutics's financial position?


In this section we usually analyse Calmare Therapeutics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Calmare Therapeutics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

Dividend

What is Calmare Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Calmare Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Calmare Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Calmare Therapeutics has not reported any payouts.

Unable to verify if Calmare Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Calmare Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Calmare Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Conrad Mir (50yo)

5.8yrs

Tenure

US$279,000

Compensation

Mr. Conrad F. Mir has been the Chief Executive Officer and President of Calmare Therapeutics Incorporated since September 27, 2013. Mr. Mir served as Interim Chief Financial Officer of Competitive Technolo ...


CEO Compensation Analysis

Insufficient data for Conrad to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.

No earnings data for Calmare Therapeutics, not possible to compare to compensation.


Management Age and Tenure

3.8yrs

Average Tenure

66yo

Average Age

The tenure for the Calmare Therapeutics management team is about average.


Board Age and Tenure

9.3yrs

Average Tenure

64yo

Average Age

The tenure for the Calmare Therapeutics board of directors is about average.


Insider Trading

No 3 month individual insider trading information.


Ownership Breakdown


Management Team

  • Conrad Mir (50yo)

    President

    • Tenure: 5.8yrs
    • Compensation: $279.00k
  • Thomas Richtarich (66yo)

    Chief Financial Officer

    • Tenure: 3.5yrs
    • Compensation: $113.02k
  • Stephen D'Amato (71yo)

    Chief Medical Officer & Member of Medical Advisory Board

    • Tenure: 3.8yrs
  • Bill Lipford

    Division Head of Product Sales

    • Tenure: 4.9yrs
  • Donna Mays

    Manager of Administrative Services

    • Tenure: 3.3yrs

Board Members

  • Conrad Mir (50yo)

    President

    • Tenure: 5.8yrs
    • Compensation: $279.00k
  • Stan Yarbro (69yo)

    Independent Director

    • Tenure: 7.3yrs
    • Compensation: $28.88k
  • Peter Brennan (64yo)

    Chairman of the Board

    • Tenure: 7.2yrs
    • Compensation: $22.98k
  • Rus Howard (62yo)

    Independent Director

    • Tenure: 11.8yrs
    • Compensation: $21.48k
  • Marco Pappagallo

    Member of Medical Advisory Board

    • Tenure: 9.3yrs
  • Stephen D'Amato (71yo)

    Chief Medical Officer & Member of Medical Advisory Board

    • Tenure: 9.3yrs
  • Subash Jain

    Member of Medical Advisory Board

    • Tenure: 9.3yrs
  • Lauren Shaiova

    Member of Medical Advisory Board

    • Tenure: 9.3yrs

Company Information

Calmare Therapeutics Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Calmare Therapeutics Incorporated
  • Ticker: CTTC
  • Exchange: OTCPK
  • Founded: 1968
  • Industry: health care equipment
  • Sector: healthcare
  • Market Cap: US$7.644m
  • Shares outstanding: 39.00m
  • Website: Click here

Number of Employees


Location

  • Calmare Therapeutics Incorporated
  • 1375 Kings Highway East
  • Suite 400
  • Fairfield
  • Connecticut
  • 6824
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTTCOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 1973

Biography

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/17 23:35
End of Day Share Price2019/07/16 00:00
Earnings2016/12/31
Annual Earnings2016/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.